The Journal of Thoracic and Cardiovascular Surgery
Volume 133, Issue 5 , Pages 1137-1146 , May 2007

Endothelin-1 accentuates the proatherosclerotic effects associated with C-reactive protein

Read at the Eighty-sixth Annual Meeting of The American Association for Thoracic Surgery, Philadelphia, Pa, April 29-May 3, 2006.

  • Danny Ramzy, MD

      Affiliations

    • Division of Cardiac Surgery, University of Toronto, Toronto, Ontario, Canada
    • ,
  • Vivek Rao, MD, PhD

      Affiliations

    • Division of Cardiac Surgery, University of Toronto, Toronto, Ontario, Canada
    • Corresponding Author InformationAddress for reprints: Vivek Rao, MD, PhD, FRCS, Alfredo and Teresa DeGasperis Chair in Heart Failure Surgery, 4N-464, Toronto General Hospital, 200 Elizabeth Street, Toronto, Ontario, M5G 2C4, Canada
    • ,
  • Laura C. Tumiati, BSc

      Affiliations

    • Division of Cardiac Surgery, University of Toronto, Toronto, Ontario, Canada
    • ,
  • Ning Xu, MD, MSc

      Affiliations

    • Division of Cardiac Surgery, University of Toronto, Toronto, Ontario, Canada
    • ,
  • Rohit Sheshgiri, BSc

      Affiliations

    • Heart Transplant Program, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada
    • ,
  • Jessica Jackman, BSc

      Affiliations

    • Heart Transplant Program, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada
    • ,
  • Diego H. Delgado, MD

      Affiliations

    • Division of Cardiology, University of Toronto, Toronto, Ontario, Canada.
    • ,
  • Heather J. Ross, MD, MSc

      Affiliations

    • Division of Cardiology, University of Toronto, Toronto, Ontario, Canada.

Received 28 April 2006 ,Revised 18 October 2006 ,Accepted 1 November 2006.

References 

  1. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411–415
  2. Luscher TF. Endothelin (Key to coronary vasospasm?). Circulation. 1991;83:701–703
  3. Rubanyi GM, Polokoff MA. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev. 1994;46:325–415
  4. Berkenboom G, Giot C, Unger P, Vachiery JL, Antoine M, LeClerc JL. Plasma endothelin and early coronary endothelial dysfunction in recipients of a cardiac transplant. Am Heart J. 1995;129:1178–1184
  5. Fedak PW, Rao V, Verma S, Ramzy D, Tumiati L, Miriuka S, et al. Combined endothelial and myocardial protection by endothelin antagonism enhances transplant allograft preservation. J Thorac Cardiovasc Surg. 2005;129:407–415
  6. Vassalli G, Gallino A Microcirculation Working Group, European Society of Cardiology. Endothelial dysfunction and accelerated coronary artery disease in cardiac transplant recipients. Eur Heart J. 1997;18:1712–1717
  7. Weis M, Wildhirt SM, Schulze C, Rieder G, Wilbert-Lampen U, Wolf WP, et al. Endothelin in coronary endothelial dysfunction early after human heart transplantation. J Heart Lung Transplant. 1999;18:1071–1079
  8. Dong F, Zhang X, Wold LE, Ren Q, Zhang Z, Ren J. Endothelin-1 enhances oxidative stress, cell proliferation and reduces apoptosis in human umbilical vein endothelial cells: role of ET(B) receptor, NADPH oxidase and caveolin-1. Br J Pharmacol. 2005;145:323–333
  9. Wedgwood S, Black SM. Endothelin-1 decreases endothelial NOS expression and activity through ETA receptor-mediated generation of hydrogen peroxide. Am J Physiol Lung Cell Mol Physiol. 2005;288:L480–L487
  10. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801–809
  11. Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med. 1999;340:115–126
  12. Rifai N, Ridker PM. High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin Chem. 2001;47:403–411
  13. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA. 2001;285:2481–2485
  14. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286:327–334
  15. Blake GJ, Ridker PM. Inflammatory mechanisms in atherosclerosis: from laboratory evidence to clinical application. Ital Heart J. 2001;2:796–800
  16. Rifai N, Buring JE, Lee IM, Manson JE, Ridker PM. Is C-reactive protein specific for vascular disease in women?. Ann Intern Med. 2002;136:529–533
  17. Albert CM, Ma J, Rifai N, Stampfer MJ, Ridker PM. Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation. 2002;105:2595–2599
  18. Blake GJ, Ridker PM. C-reactive protein and other inflammatory risk markers in acute coronary syndromes. J Am Coll Cardiol. 2003;41(4 suppl S):37S–42S
  19. Ridker PM, Morrow DA. C-reactive protein, inflammation, and coronary risk. Cardiol Clin. 2003;21:315–325
  20. Libby P, Ridker PM. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med. 2004;116(suppl 6A):9S–16S
  21. Verma S, Wang CH, Li SH, Dumont AS, Fedak PW, Badiwala MV, et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation. 2002;106:913–919
  22. Dlugosz JA, Munk S, Zhou X, Whiteside CI. Endothelin-1-induced mesangial cell contraction involves activation of protein kinase C-alpha, -delta, and -epsilon. Am J Physiol. 1998;275(3 Pt 2):F423–F432
  23. Park WS, Ko EA, Han J, Kim N, Earm YE. Endothelin-1 acts via protein kinase C to block KATP channels in rabbit coronary and pulmonary arterial smooth muscle cells. J Cardiovasc Pharmacol. 2005;45:99–108
  24. Ikonomidis JS, Shirai T, Weisel RD, Derylo B, Rao V, Whiteside CI, et al. Preconditioning cultured human pediatric myocytes requires adenosine and protein kinase C. Am J Physiol. 1997;272(3 Pt 2):H1220–H1230
  25. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248–254
  26. Matsubara M, Hayashi N, Jing T, Titani K. Regulation of endothelial nitric oxide synthase by protein kinase C. J Biochem (Tokyo). 2003;133:773–781
  27. Partovian C, Zhuang Z, Moodie K, Lin M, Ouchi N, Sessa WC, et al. PKCalpha activates eNOS and increases arterial blood flow in vivo. Circ Res. 2005;97:482–487
  28. Naruse K, Rask-Madsen C, Takahara N, Ha SW, Suzuma K, Way KJ, et al. Activation of vascular protein kinase C-beta inhibits Akt-dependent endothelial nitric oxide synthase function in obesity-associated insulin resistance. Diabetes. 2006;55:691–698
  29. Lee TS, Chao T, Hu KQ, King GL. Endothelin stimulates a sustained 1,2-diacylglycerol increase and protein kinase C activation in bovine aortic smooth muscle cells. Biochem Biophys Res Commun. 1989;162:381–386
  30. Lee TS, Hu KQ, Chao T, King GL. Characterization of endothelin receptors and effects of endothelin on diacylglycerol and protein kinase C in retinal capillary pericytes. Diabetes. 1989;38:1643–1646
  31. McNair LL, Salamanca DA, Khalil RA. Endothelin-1 promotes Ca2+ antagonist-insensitive coronary smooth muscle contraction via activation of epsilon-protein kinase C. Hypertension. 2004;43:897–904
  32. Robin P, Boulven I, Desmyter C, Harbon S, Leiber D. ET-1 stimulates ERK signaling pathway through sequential activation of PKC and Src in rat myometrial cells. Am J Physiol Cell Physiol. 2002;283:C251–C260
  33. Verma S, Li SH, Badiwala MV, Weisel RD, Fedak PW, Li RK, et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation. 2002;105:1890–1896
  34. Gonon AT, Erbas D, Broijersen A, Valen G, Pernow J. Nitric oxide mediates protective effect of endothelin receptor antagonism during myocardial ischemia and reperfusion. Am J Physiol Heart Circ Physiol. 2004;286:H1767–H1774
  35. Barton M, Haudenschild CC, d’Uscio LV, Shaw S, Munter K, Luscher TF. Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A. 1998;95:14367–14372
  36. Li L, Roumeliotis N, Sawamura T, Renier G. C-reactive protein enhances LOX-1 expression in human aortic endothelial cells: relevance of LOX-1 to C-reactive protein-induced endothelial dysfunction. Circ Res. 2004;95:877–883

 Supported by the Heart and Stroke Foundation of Ontario (Grant # NA 5868), the Canadian Institutes for Health Research, the Thoracic Surgery Foundation for Research and Education, the Tailored Advanced Collaborative Training in Cardiovascular Science for Research Fellows, and the Physician Services Incorporated Foundation Grant for Research Fellows. D.R. is a Research Fellow of the TSFRE, PSI and TACTICS; V.R. is a CIHR New Investigator.

 Manuscript accepted for the C. Walton Lillehei Resident Forum Session at the Annual Meeting of the American Association for Thoracic Surgery.

PII: S0022-5223(06)02277-X

doi: 10.1016/j.jtcvs.2006.11.034

The Journal of Thoracic and Cardiovascular Surgery
Volume 133, Issue 5 , Pages 1137-1146 , May 2007

Article Tools

* Image Usage & Resolution